Patient considerations in the management of type 2 diabetes - critical appraisal of dapaglifozin

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 493-502

  Salvo, Marissa C ^a   Brooks, Amie D ^b   Thacker, Stacey M ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

Pharmacological treatment; Selective sodium glucose co transporter 2 inhibitors; SGLT2 inhibitor

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; METFORMIN; PIOGLITAZONE; PLACEBO; SIMVASTATIN; SITAGLIPTIN; VALSARTAN; WARFARIN;

ADD ON THERAPY; AREA UNDER THE CURVE; BODY WEIGHT DISORDER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PREVALENCE; REVIEW; WEIGHT GAIN;

EID: 84899137508     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S59169     Document Type: Review

References (51)

1. International Diabetes Federation. Diabetes: facts and figures [cited 2013 Nov 16]. Available from: http://www.idf.org/worlddiabetesday/toolkit/gp/facts-fgures.
2. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013;36:S11-S66.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1334-1379.
4. American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm. Endocr Pract. 2013;19(2): 327-336.
5. Nichols GA, Kimes TM, Harp JB, Kou TD, Brodovicz KG. Glycemic response and attainment of A1c goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care. 2012;35(3):495-497.
6. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the US. National Health and Nutrition Examination Survey. 1999-2004. Ann Epidemiol. 2008;18(3): 222-229.
7. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83-88.
8. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249-1258.
9. Actos [package insert]. Deerfeld, IL: Takeda Pharmaceutical; 2013.
10. Precose [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals; 2011.
11. Byetta [package insert]. San Diego, CA: Amylin Pharmaceutical; 2011.
12. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk; 2013.
13. AstraZeneca, Bristol-Myers Squibb [press release]. US FDA acknowledges receipt of resubmission of the new drug application for investigational compound dapaglifozin for the treatment of type 2 diabetes [cited August 1, 2013]. MarketWatch The Wall Street Journal. July 25, 2013. Available from: http://www.marketwatch.com/story/us_fda_acknowledges_receipt_of_resubmission-of-the-new-drug-application-for-investigational-compound-dapaglifozin-for-the-treatment-of-type-2-diabetes-2013-07-25.
14. Farxiga [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2014.
15. Moe OW, Baum M, Berry CA, Rector FC Jr. Renal transport of glucose, amino acids, sodium, chloride, and water. In: Brenner BM, editor. Brenner and Rector's the Kidney. Philadelphia: WB Saunders; 1996: 413-452.
16. Deetjen P, von Baeyer H, Drexel H. Renal glucose transport. In: Seldin DW, Giebisch G, editors. Seldin and Giebisch's the Kidney, 2nd ed. NewYork: Raven Press; 1992:2873-2888.
17. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs. 2007;8(4):285-292.
18. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycae-mic control in patients with diabetes. Int J Clin Pract. 2008;62(8): 1279-1284.
19. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272-1277.
20. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-559.
21. Neumiller J, White JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377-385.
22. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14(6):782-790.
23. Plosker GL. Dapaglifozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289-2312.
24. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-274.
25. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31-38.
26. Forxiga [prescribing information]. Available from: http://www.forxiga.eu/prescribing_information. Accessed November 16, 2013.
27. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapaglifozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride, or sitagliptin in healthy subjects Diabetes Obes Metab. 2011;13:47-54.
28. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapaglifozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163-177.
29. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapaglifozin in monotherapy in type 2 diabetes patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-2224.
30. Bailey CJ, Iqbal N, T'joen C, List JF. Dapaglifozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951-959.
31. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapaglifozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233.
32. Bailey CJ, Gross JL, Hennicken D, et al. Dapaglifozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.
33. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapaglifozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020-1031.
34. Strojek K, Yoon KH, Hruba V, et al. Effect of dapaglifozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928-938.
35. Wilding J P, Woo V, Soler N, et al. Long-term effcacy of dapaglifozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med. 2012;156(6):405-415.
36. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapaglifozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473-1478.
37. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapaglifozin is effective as add-on therapy to sitagliptin with or without metformin: a 24 week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. January 15, 2014. [Epub ahead of print.]
38. Nauck MA, Del Prato S, Meier JJ, et al. Dapaglifozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9): 2015-2022.
39. Henry RR, Murray AV, Marmolejo MH, et al. Dapaglifozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446-456.
40. Bristol-Myers Squibb [press release]. New phase III data showed dapa-glifozin significantly reduced AbA1c compared to placebo at 24 weeks in patients with type 2 diabetes inadequately controlled with the combination of metformin plus sulfonylurea. Available from: http://news.bms.com/press-release/rd-news/new-phase-iii-data-showed_dapaglifozin_signifcantly_reduced_hba1c_compared_p&t=635156160653787526. Accessed September 25, 2013.
41. Vallon V, Sharma K. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens. 2010;19(5):425-431.
42. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glycosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520-526.
43. US Food and Drug Administration. FDA briefng document: NDA 202293 dapaglifozin 5 and 10 mg. July 19, 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/Committees_MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf. Accessed November 12, 2013.
44. Bristol-Myers Squibb, AstraZeneca. NDA 202293 dapagliflozin: Endocrinologic and Metabolic Advisory Committee background document. July 13, 2011. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrino-logicandmetabolicdrugsadvisorycommittee/ucm378079.pdf. Accessed November 12, 2013.
45. Wilding JP, Norwood P, T'joen C, et al. A study of dapaglifozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656-1662.
46. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapaglifozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-657.
47. Stein J. Urinary tract infections more common in diabetics. Renal and Urology News. July 8, 2013. Available from: http://www.renalandurol_ogynews.com/urinary_tract_infections-more-common-in-diabetics/article/302056. Accessed January 13, 2014.
48. Adul-Ghani MA, DeFronzo RA. Dapaglifozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2013;14(12):1695-1703.
49. Kasichayanula S, Liu X, Zhang W, et al. Infuence of hepatic impairment on the pharmacokinetics and safety profle of dapaglifozin: an open-label, parallel group, single-dose study. Clin Ther. 2011;33(11): 1798-1808.
50. Komoroski B, Vachharajani N, Feng Y, et al. Dapaglifozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5): 513-519.
51. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2014.